前收市價 | 9.90 |
開市 | 9.50 |
買盤 | 0.00 |
賣出價 | 0.00 |
拍板 | 335.00 |
到期日 | 2024-10-18 |
今日波幅 | 9.05 - 9.90 |
合同範圍 | 無 |
成交量 | |
未平倉合約 | 無 |
Sunday, Amgen Inc (NASDAQ:AMGN) and AstraZeneca Plc (NASDAQ:AZN) announced the results of the Phase 2a COURSE trial of Tezspire (tezepelumab-ekko) for severe chronic obstructive pulmonary disease (COPD) with a broad range of baseline blood eosinophil counts (BEC) irrespective of emphysema, chronic bronchitis or smoking status. The primary results showed that treatment with Tezspire led to a 17% numerical reduction in the annual rate of moderate or severe COPD exacerbations compared to placebo at
Novo Nordisk, Eli Lilly's, Viking, Altimmune, Roche and Amgen are included in this Analyst Blog.
Eli Lilly's biggest growth drivers today are its weight loss drugs.